Akebia Therapeutics (STU:AX9) Other Current Payables: €4.3 Mil (As of Mar. 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
47 GF Score
Price €1.08
GF Value €1.13
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Other Current Payables?

Akebia Therapeutics STU:AX9 +1.31% 47 Other Current Payables is €4.3 Mil as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 47/100 and a GF Value™ of €1.13 (Fairly Valued). The stock has 5 warning signs investors should review.

Akebia Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was €4.3 Mil.

Akebia Therapeutics's quarterly Other Current Payables increased from Sep. 2025 (€0.0 Mil) to Dec. 2025 (€4.3 Mil) and increased from Dec. 2025 (€4.3 Mil) to Mar. 2026 (€4.3 Mil).

Akebia Therapeutics's annual Other Current Payables stayed the same from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€0.0 Mil) but then increased from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€4.3 Mil).

Akebia Therapeutics Other Current Payables Related Terms

Akebia Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Other Current Payables Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.27

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 4.27 4.33
STU:AX9
47GF Score
Akebia Therapeutics Inc STU:AX9
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €4.3 Mil mean?
Akebia Therapeutics (STU:AX9) has a Other Current Payables of €4.3 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Other Current Payables too high?
Akebia Therapeutics' current Other Current Payables is €4.3 Mil. Overall, Akebia Therapeutics has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Other Current Payables compare to TKNO and ORGO?
Akebia Therapeutics' Other Current Payables of €4.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Other Current Payables is €4.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.13, compared to a current price of €1.08 — trading 4.5% below its estimated fair value. The current Other Current Payables is €4.3 Mil. Akebia Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Other Current Payables is €4.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €1.08 is trading 4.5% below its estimated GF Value™ of €1.13. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Other Current Payables: €4.3 Mil
  • GF Value™: €1.13 vs. price of €1.08 (4.5% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score

Get the complete analysis for STU:AX9

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.08
Price
€1.13
GF Value